Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CAD | P27708 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468762 | 1.00 | L3MBTL1 (0.75) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL12357113 | 0.90 | L3MBTL1 (0.62) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL21274418 | 0.88 | L3MBTL1 (0.58) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL11124589 | 0.88 | L3MBTL1 (0.58) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL21274419 | 0.88 | L3MBTL1 (0.58) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL7599579 | 0.87 | L3MBTL1 (0.77) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL11124586 | 0.86 | L3MBTL1 (0.56) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL15730803 | 0.86 | L3MBTL1 (1.00) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL468757 | 0.84 | L3MBTL1 (0.54) | L3MBTL1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL4189297 | 0.84 | L3MBTL1 (0.84) | L3MBTL1KMT2APOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | claimed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | US | disclosed |
| US-7453010-B2 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| US-7453010-B2 | Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof | SANOFI AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | AADAC, ACAT2, AANAT | L3MBTL1 2249/4885KMT2A 698/4885POLB 3332/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | L3MBTL1 2366/4885KMT2A 1449/4885POLB 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.